In response to growing concerns about sustainability, switching to more environmentally friendly pressurized metered-dose inhaler (pMDI) propellants has become a high priority for the pharmaceutical industry. Since inhalation devices contribute three percent of global emissions, this is an important step. In addition to being a part of a greener future, transitioning to a low global warming potential (GWP) propellant now positions companies as leaders in sustainability and innovation and aligns products with current and evolving regulations and standards.
However, while this transition to the next generation of propellants creates more sustainable products, it is essential to ensure performance is not diminished as a result. New low GWP candidate propellants have different physicochemical and thermodynamic properties compared to current options. Therefore, simply switching to a green propellant without any other adjustments to an existing formulation is not feasible. Understanding the impact of propellent property differences on pMDI performance is crucial to enable the development of reformulated or new pMDI products employing low GWP propellant gasses while ensuring these products continue to perform effectively and safely for the patients who rely on them.
During this webinar, participants can expect comprehensive coverage of critical topics surrounding green pMDI propellant properties. The session will delve into the distinctions between low GWP propellants, emphasizing their far-reaching implications for droplet production and overall product performance. The webinar will showcase a diverse array of investigations, incorporating innovative techniques such as high-speed imaging and X-ray diagnostics, alongside pharmacopeial performance experiments. These methodologies have been thoughtfully employed to explore the significant impacts associated with transitioning propellants in pMDI products. Attendees will receive information to assist them in tuning the performance of low GWP propellants effectively.
Benjamin Myatt, R&D Staff Scientist, Kindeva Drug Delivery
Ben Myatt is a Senior Product Development Engineer within R&D at Kindeva Drug Delivery. His work focuses on next-generation low GWP propellants: evaluating and developing current and new inhalation technologies and device platforms and developing new test methodologies and novel apparatus to measure, understand and enable new pMDI product development. Ben is a chartered mechanical engineer and a member of the Institute of Mechanical Engineers.
Prior to joining Kindeva, Ben gained a MEng in Mechanical Engineering from Loughborough University. He then conducted PhD research in the thermofluids and optical diagnostic groups, focusing on pMDI atomization using non-contact laser-based and high-speed imaging techniques to investigate pMDI internal fluid flows and spray plumes. Ben’s goal is to delve deeper into the science of pMDIs to understand and improve pMDI drug delivery and efficiency and enable new pMDI products and ultimately improved therapeutic outcomes.
Daniel Duke, Senior Lecturer, Mechanical & Aerospace Engineering, Monash University
Daniel Duke is a Senior Lecturer in the Department of Mechanical & Aerospace Engineering at Monash University (Clayton Campus), where he leads two active ARC Projects.
His area of research is turbulent multi-phase fluid flows and he specializes in the development and application of synchrotron x-ray diagnostics, optical diagnostics and high-performance computing tools for studying these problems. His current work concerns the development of synchrotron diagnostics for the study of cavitation, liquid atomization and particle formation in medical sprays.
Daniel is a former ARC DECRA Fellow and a Fulbright Scholar. He received his PhD in Mechanical Engineering from Monash in 2013.
Who Should Attend?
Senior professionals from pharma, biotech and medical device organizations, including:
- Manufacturing Process and Development — VP of External Manufacturing
- Commercial Lead
- Manufacturing and/or Process Engineering Manager (Director, Head or VP)
- Formulation Scientists
- VP/Heads/Managers of R&D
What You Will Learn
- The differences in pMDI propellant properties and implications of low GWP options for droplet production and product performance
- A range of investigations undertaken, including novel high-speed imaging and X-ray diagnostics and pharmacopeial performance experiments, to explore the impact of switching to green propellants in pMDI products
- A summary of key findings and insights to enable tuning of low GWP pMDI product performance
Kindeva is a global contract development and manufacturing organization focused on drug-device combination products. We develop and manufacture products across a broad range of drug-delivery formats, including pulmonary & nasal, injectable, and transdermal. Our service offerings span early-stage feasibility through commercial scale drug product fill-finish, container closure system manufacturing, and drug-device product assembly. Kindeva serves a global client base from our nine manufacturing, research, and development facilities located in the U.S. and U.K.